Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats.
Saved in:
| Title: | Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats. |
|---|---|
| Authors: | Skarbaliene J; Research and Development, Zealand Pharma A/S, Sydmarken 11, 2860, Søborg, Denmark.; Pharvaris GmbH, 6300, Grafenauweg 8, Zug, Switzerland., Mathiesen JM; Research and Development, Zealand Pharma A/S, Sydmarken 11, 2860, Søborg, Denmark. jmmathiesen@zealandpharma.com., Larsen BD; Research and Development, Zealand Pharma A/S, Sydmarken 11, 2860, Søborg, Denmark., Thorkildsen C; Research and Development, Zealand Pharma A/S, Sydmarken 11, 2860, Søborg, Denmark., Petersen YM; Research and Development, Zealand Pharma A/S, Sydmarken 11, 2860, Søborg, Denmark.; Hoffmann-La Roche, Grenzacherstrasse 124, 4070, Basel, Switzerland. |
| Source: | BMC gastroenterology [BMC Gastroenterol] 2023 Mar 21; Vol. 23 (1), pp. 79. Date of Electronic Publication: 2023 Mar 21. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X (Electronic) Linking ISSN: 1471230X NLM ISO Abbreviation: BMC Gastroenterol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1471-230X |
|---|---|
| DOI: | 10.1186/s12876-023-02716-4 |
